Acalabrutinib shows improved cardiovascular safety over ibrutinib, reducing atrial fibrillation and hypertension risks in CLL patients. Real-world data confirm ELEVATE-RR trial results, highlighting ...

Lorna Warwick, CEO of the Lymphoma Coalition, highlights findings underscoring the vital role of clinician communication in managing adverse effects and supporting patient confidence in lymphoma and ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...